The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. AZ has received a notice ...

AstraZeneca Q4 revenue rose 18% to $14.89 billion, surpassing estimates, with oncology sales up 27% to $6.34 billion. FY25 guidance projects high single-digit revenue growth and low double-digit ...

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the ...

WILMINGTON, Del., January 27, 2025--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable ...

Rachel Reeves was dealt yet another blow after AstraZeneca cancelled a planned £450 million investment in a vaccine manufacturing plant. The chancellor came under fire on GB News for "making an ...

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, its chief strategy officer and Alexion CEO Marc Dunoyer said in a meeting ...

MANILA, Philippines — Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in conducting most of its clinical trials in the ...

AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden’s Astra AB and ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...